JP2024532485A5 - - Google Patents

Info

Publication number
JP2024532485A5
JP2024532485A5 JP2024513933A JP2024513933A JP2024532485A5 JP 2024532485 A5 JP2024532485 A5 JP 2024532485A5 JP 2024513933 A JP2024513933 A JP 2024513933A JP 2024513933 A JP2024513933 A JP 2024513933A JP 2024532485 A5 JP2024532485 A5 JP 2024532485A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
region sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532485A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/075846 external-priority patent/WO2023034922A2/en
Publication of JP2024532485A publication Critical patent/JP2024532485A/ja
Publication of JP2024532485A5 publication Critical patent/JP2024532485A5/ja
Pending legal-status Critical Current

Links

JP2024513933A 2021-09-03 2022-09-01 Cd137および腫瘍関連抗原に結合する二重特異性結合タンパク質 Pending JP2024532485A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163240402P 2021-09-03 2021-09-03
US63/240,402 2021-09-03
US202263327700P 2022-04-05 2022-04-05
US63/327,700 2022-04-05
PCT/US2022/075846 WO2023034922A2 (en) 2021-09-03 2022-09-01 Bispecific binding proteins that bind cd137 and a tumor associated antigen

Publications (2)

Publication Number Publication Date
JP2024532485A JP2024532485A (ja) 2024-09-05
JP2024532485A5 true JP2024532485A5 (cg-RX-API-DMAC7.html) 2025-09-05

Family

ID=85413134

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513933A Pending JP2024532485A (ja) 2021-09-03 2022-09-01 Cd137および腫瘍関連抗原に結合する二重特異性結合タンパク質

Country Status (7)

Country Link
US (1) US20240383978A1 (cg-RX-API-DMAC7.html)
EP (1) EP4395823A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532485A (cg-RX-API-DMAC7.html)
KR (1) KR20240073008A (cg-RX-API-DMAC7.html)
AU (1) AU2022337286A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230426A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023034922A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008500A (es) * 2022-01-09 2024-08-26 I Mab Biopharma Co Ltd Construcciones multiespecíficas y usos de estas.
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564432A1 (en) * 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
JP2011524179A (ja) * 2008-06-16 2011-09-01 パトリス リミテッド Lm−1抗体、機能性フラグメント、lm−1標的抗原、ならびにそれらを作製および使用するための方法
CN106459165B (zh) * 2014-04-01 2021-04-20 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
EP3554544A4 (en) * 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
CN112020516B (zh) * 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
WO2020191344A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
US11261259B2 (en) * 2019-08-12 2022-03-01 I-Mab Biopharma Us Limited Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
JP2022545835A (ja) * 2019-08-28 2022-10-31 ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー 甲状腺眼症の治療方法
CA3164996A1 (en) * 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
PH12022552323A1 (en) * 2020-03-31 2023-12-04 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
EP4301784A4 (en) * 2021-03-02 2025-01-01 NovaRock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof

Similar Documents

Publication Publication Date Title
Wu et al. Building blocks for bispecific and trispecific antibodies
JP7549961B2 (ja) 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP6669722B2 (ja) Cd3結合ドメイン
JP2023082067A (ja) 改良された抗原結合受容体
RU2355705C2 (ru) Одноцепочечное цикличное триспецифическое антитело
WO2015063187A1 (en) Multivalent antigen-binding proteins
JP2023518134A5 (cg-RX-API-DMAC7.html)
Xiong et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody
JP2016514676A (ja) 四価二重特異性抗体
CN103687879A (zh) 多价抗原结合fv分子
CN115066274A (zh) 三价结合分子
JP2024001073A5 (cg-RX-API-DMAC7.html)
JP2025508316A5 (cg-RX-API-DMAC7.html)
CN113150156B (zh) 抗tigit抗体及其用途
JP2024504162A5 (cg-RX-API-DMAC7.html)
Acheampong Bispecific antibody (bsAb) construct formats and their application in cancer therapy
JP2025512953A5 (cg-RX-API-DMAC7.html)
JP2024541476A5 (cg-RX-API-DMAC7.html)
JP2024546923A5 (cg-RX-API-DMAC7.html)
WO2021113748A1 (en) Composition of triaxial antibodies and method of making and using thereof
CN113825772A (zh) 抗her2亲合体及将其用作开关分子的可切换嵌合抗原受体
Li et al. Advancing immunotherapy via multiple immune cells co-engagement
JP2025505611A5 (cg-RX-API-DMAC7.html)
JP2022550120A5 (cg-RX-API-DMAC7.html)